Author, as appears in the article.: Cariolou M; Markozannes G; Becerra-Tomás N; Vieira R; Balducci K; Aune D; Muller DC; Chan DSM; Tsilidis KK
Department: Ciències Mèdiques Bàsiques
URV's Author/s: Becerra Tomás, Nerea
Keywords: Epidemiology Prostatic diseases
Abstract: To explore the associations between adiposity indices, assessed at or after a diagnosis of prostate cancer, and mortality.Systematic review and meta-analysis.PubMed and Embase, from inception to 16 November 2022.Cohort studies or randomised controlled trials of men with a diagnosis of prostate cancer that investigated the associations between adiposity (body mass index, waist and hip circumference, waist-to-hip ratio, and subcutaneous and visceral adipose tissue) after diagnosis and mortality outcomes. A modified version of the risk of bias for nutrition observational studies tool was used to assess risk of bias.79 studies were identified that investigated adiposity indices after a diagnosis of prostate cancer in relation to mortality. No randomised controlled trials were found. A non-linear dose-response meta-analysis indicated a J shaped association between body mass index and all cause mortality (33 910 men, 11 095 deaths, 17 studies). The highest rate of all cause mortality was found at the lowest and upper range of the distribution: 11-23% higher rate for a body mass index of 17-21 and 4-43% higher rate for a body mass index of 30-40. The association between body mass index and mortality specific to prostate cancer was flat until body mass index reached 26-27, and then increased linearly by 8-66% for a body mass index of 30-40 (33 137 men, 2947 deaths, 13 studies), but the 95% confidence intervals were wide. These associations did not differ in most predefined subgroups by study design, number of deaths, anthropometric assessment, follow-up time, geographical location, prostate cancer risk group, and adjustment variables. No associations were found in meta-analyses between 10 cm increases in waist circumference and all cause mortality or mortality specific to prostate cancer, but only three studies were available. The few studies with data on change in weight, waist-to-hip ratio, and subcutaneous and visceral adipose tissue reported conflicting results.This review suggests that patients with prostate cancer might benefit from maintaining a healthy weight and avoiding obesity. Future studies should investigate adiposity across different stages of cancer survivorship and use various parameters for distribution of adipose tissue.Open Science Framework https://osf.io/qp3c4.© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: nerea.becerra@urv.cat
Author identifier: 0000-0002-4429-6507
Record's date: 2024-03-01
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://bmjmedicine.bmj.com/content/2/1/e000339
Papper original source: Bmj Medicine. 2 (1): e000339-e000339
APA: Cariolou M; Markozannes G; Becerra-Tomás N; Vieira R; Balducci K; Aune D; Muller DC; Chan DSM; Tsilidis KK (2023). Association between adiposity after diagnosis of prostate cancer and mortality: systematic review and meta-analysis. Bmj Medicine, 2(1), e000339-e000339. DOI: 10.1136/bmjmed-2022-000339
Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
Article's DOI: 10.1136/bmjmed-2022-000339
Entity: Universitat Rovira i Virgili
Journal publication year: 2023
Publication Type: Journal Publications
Repositori URV